|
1
|
de Villiers TJ and Goldstein SR: Bone
health 2022: An update. Climacteric. 25:1–3. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Borgström F, Karlsson L, Ortsäter G,
Norton N, Halbout P, Cooper C, Lorentzon M, McCloskey EV, Harvey
NC, Javaid MK, et al: Fragility fractures in Europe: Burden,
management and opportunities. Arch Osteoporos.
15(59)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hanafusa N, Abe M, Joki N, Hoshino J,
Kikuchi K, Goto S, Kanda E, Taniguchi M, Nakai S, Naganuma T, et
al: Annual dialysis data report. 2020, JSDT Renal Data Registry.
Ren Replace Ther. 10(14)2024.
|
|
4
|
GBD Chronic Kidney Disease Collaboration.
Global, regional, and national burden of chronic kidney disease,
1990-2017: A systematic analysis for the global burden of disease
study 2017. Lancet. 395:709–733. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nickolas TL, McMahon DJ and Shane E:
Relationship between moderate to severe kidney disease and hip
fracture in the United States. J Am Soc Nephrol. 17:3223–3232.
2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tentori F, McCullough K, Kilpatrick RD,
Bradbury BD, Robinson BM, Kerr PG and Pisoni RL: High rates of
death and hospitalization follow bone fracture among hemodialysis
patients. Kidney Int. 85:166–173. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen CH, Lo WC, Hu PJ, Chan HC, Shen WC,
Wu MS and Wu MY: Efficacy of osteoporosis medications for patients
with chronic kidney disease: An updated systematic review and
network meta-analysis. Front Pharmacol. 13(822178)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Thongprayoon C, Acharya P, Acharya C,
Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K,
Ungprasert P, Gonzalez Suarez ML and Cheungpasitporn W:
Hypocalcemia and bone mineral density changes following denosumab
treatment in end-stage renal disease patients: A meta-analysis of
observational studies. Osteoporos Int. 29:1737–1745.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sumida K, Ubara Y, Hoshino J, Mise K,
Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E,
et al: Once-weekly teriparatide in hemodialysis patients with
hypoparathyroidism and low bone mass: A prospective study.
Osteoporos Int. 27:1441–1450. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cosman F, Crittenden DB, Adachi JD,
Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki
EM, Miyauchi A, et al: Romosozumab treatment in postmenopausal
women with osteoporosis. N Engl J Med. 375:1532–1543.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Miyauchi A, Hamaya E, Nishi K, Tolman C
and Shimauchi J: Efficacy and safety of romosozumab among Japanese
postmenopausal women with osteoporosis and mild-to-moderate chronic
kidney disease. J Bone Miner Metab. 40:677–687. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Miller PD, Adachi JD, Albergaria BH,
Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M,
Reid IR, et al: Efficacy and safety of romosozumab among
postmenopausal women with osteoporosis and mild-to-moderate chronic
kidney disease. J Bone Miner Res. 37:1437–1445. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
LaClair RE, Hellman RN, Karp SL, Kraus M,
Ofner S, Li Q, Graves KL and Moe SM: Prevalence of calcidiol
deficiency in CKD: A cross-sectional study across latitudes in the
United States. Am J Kidney Dis. 45:1026–1033. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Craver L, Marco MP, Martínez I, Rue M,
Borràs M, Martín ML, Sarró F, Valdivielso JM and Fernández E:
Mineral metabolism parameters throughout chronic kidney disease
stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial
Transplant. 22:1171–1176. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kidney Disease: Improving Global Outcomes
(KDIGO) CKD-MBD Update Work Group: KDIGO 2017 clinical practice
guideline update for the diagnosis, evaluation, prevention, and
treatment of chronic kidney disease-mineral and bone disorder
(CKD-MBD). Kidney Int Suppl (2011). 7:1–59. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pluskiewicz W, Adamczyk P, Czekajło A,
Grzeszczak W, Burak W and Drozdzowska B: Epidemiological data on
osteoporosis in women from the RAC-OST-POL study. J Clin Densitom.
15:308–314. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
United Nations Department of Economic and
Social Affairs, Population Division. World Population Prospects
2022: Summary of Results. UN DESA/POP/2022/TR/NO. 3, 2022.
|
|
18
|
Saito K, Miyakoshi N, Matsunaga T, Hongo
M, Kasukawa Y and Shimada Y: Eldecalcitol improves muscle strength
and dynamic balance in postmenopausal women with osteoporosis: An
open-label randomized controlled study. J Bone Miner Metab.
34:547–554. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ling Y, Xu F, Xia X, Dai D, Xiong A, Sun
R, Qiu L and Xie Z: Vitamin D supplementation reduces the risk of
fall in the vitamin D deficient elderly: An updated meta-analysis.
Clin Nutr. 40:5531–5537. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Matsuo S, Imai E, Horio M, Yasuda Y,
Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A:
Collaborators developing the Japanese equation for estimated GFR.
Revised equations for estimated GFR from serum creatinine in Japan.
Am J Kidney Dis. 53:982–992. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kobayakawa T, Miyazaki A, Takahashi J and
Nakamura Y: Effects of romosozumab with and without active vitamin
D analog supplementation for postmenopausal osteoporosis. Clin Nutr
Espen. 48:267–274. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
U.S. Department of Health and Human
Services. Common terminology criteria for. adverse events (CTCAE)
version 5.0. National Institutes of Health, National Cancer.
Institute, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Accessed February 27, 2025.
|
|
23
|
Faber BG, Frysz M, Boer CG, Evans DS,
Ebsim R, Flynn KA, Lundberg M, Southam L, Hartley A, Saunders FR,
et al: The identification of distinct protective and susceptibility
mechanisms for hip osteoarthritis: Findings from a genome-wide
association study meta-analysis of minimum joint space width and
Mendelian randomisation cluster analyses. EBioMedicine.
95(104759)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nakao H, Yokomoto-Umakoshi M, Nakatani K,
Umakoshi H, Ogata M, Fukumoto T, Kaneko H, Iwahashi N, Fujita M,
Ogasawara T, et al: Adrenal steroid metabolites and bone status in
patients with adrenal incidentalomas and hypercortisolism.
EBioMedicine. 95(104733)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ebeling PR, Nguyen HH, Aleksova J, Vincent
AJ, Wong P and Milat F: Secondary osteoporosis. Endocr Rev.
43:240–313. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dong L, Jiang L, Xu Z and Zhang X:
Denosumab, teriparatide and bisphosphonates for
glucocorticoid-induced osteoporosis: A Bayesian network
meta-analysis. Front Pharmacol. 15(1336075)2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu H, Xiao H, Lin S, Zhou H, Cheng Y, Xie
B and Xu D: Effect of gut hormones on bone metabolism and their
possible mechanisms in the treatment of osteoporosis. Front
Pharmacol. 15(1372399)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rodríguez V, Rivoira M, Picotto G, de
Barboza GD, Collin A and Tolosa de Talamoni N: Analysis of the
molecular mechanisms by flavonoids with potential use for
osteoporosis prevention or therapy. Curr Med Chem. 29:2913–2936.
2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yu B, Gao Q, Sheng S, Zhou F, Geng Z, Wei
Y, Zhang H, Hu Y, Wang S, Huang J, et al: Smart osteoclasts
targeted nanomedicine based on amorphous CaCO3 for effective
osteoporosis reversal. J Nanobiotechnology. 22(153)2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhao L, Cai C, Wang J, Zhao L, Li W, Liu
C, Guan H, Zhu Y and Xiao J: Dihydromyricetin. protects against
bone loss in ovariectomized mice by suppressing osteoclast
activity. Front Pharmacol. 8(928)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xu L, Sun X, Han X, Li H, Li X, Zhu L,
Wang X, Li J and Sun H: Dihydromyricetin ameliorate postmenopausal
osteoporosis in ovariectomized mice: Integrative microbiomic and
metabolomic analysis. Front Pharmacol. 15(1452921)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen YJ, Jia LH, Han TH, Zhao ZH, Yang J,
Xiao JP, Yang HJ and Yang K: Osteoporosis treatment: Current drugs
and future developments. Front Pharmacol.
15(1456796)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Deng TT, Ding WY, Lu XX, Zhang QH, Du JX,
Wang LJ, Yang MN, Yin Y and Liu FJ: Pharmacological and mechanistic
aspects of quercetin in osteoporosis. Front Pharmacol.
15(1338951)2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wu Y, Song P, Wang M, Liu H, Jing Y and Su
J: Extracellular derivatives for bone metabolism. J Adv Res.
66:329–347. 2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zeng ZL and Xie H: Mesenchymal stem
cell-derived extracellular vesicles: A possible therapeutic
strategy for orthopaedic diseases: A narrative review. Biomater
Transl. 3:175–187. 2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yeung WG, Palmer SC, Strippoli GFM, Talbot
B, Shah N, Hawley CM, Toussaint ND and Badve SV: Vitamin D therapy
in adults with CKD: A systematic review and meta-analysis. Am J
Kidney Dis. 82:543–558. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kikuta J, Kawamura S, Okiji F, Shirazaki
M, Sakai S, Saito H and Ishii M: Sphingosine-1-phosphate-mediated
osteoclast precursor monocyte migration is a critical point of
control in antibone-resorptive action of active vitamin D. Proc
Natl Acad Sci USA. 110:7009–7013. 2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
McClung MR, Grauer A, Boonen S, Bolognese
MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta
JR, Wasserman SM, et al: Romosozumab in postmenopausal women with
low bone mineral density. N Engl J Med. 370:412–420.
2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Movérare-Skrtic S, Voelkl J, Nilsson KH,
Nethander M, Luong TTD, Alesutan I, Li L, Wu J, Horkeby K,
Lagerquist MK, et al: B4GALNT3 regulates glycosylation of
sclerostin and bone mass. EBioMedicine. 91(104546)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Valverde MG, Mille LS, Figler KP,
Cervantes E, Li VY, Bonventre JV, Masereeuw R and Zhang YS:
Biomimetic models of the glomerulus. Nat Rev Nephrol. 18:241–257.
2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sakai S, Endo K, Takeda S, Mihara M and
Shiraishi A: Combination therapy with eldecalcitol and alendronate
has therapeutic advantages over monotherapy by improving bone
strength. Bone. 50:1054–1063. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Nakamura Y, Suzuki T, Kamimura M, Murakami
K, Ikegami S, Uchiyama S and Kato H: Vitamin D and calcium are
required at the time of denosumab administration during
osteoporosis treatment. Bone Res. 5(17021)2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Suzuki T, Nakamura Y and Kato H: Effects
of monthly minodronate with or without eldecalcitol addition in
osteoporosis patients with rheumatoid arthritis: An 18-month
prospective study. Osteoporos Sarcopenia. 5:122–127.
2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kondo S, Takano T, Ono Y, Saito H and
Matsumoto T: Eldecalcitol reduces osteoporotic fractures by unique
mechanisms. J Steroid Biochem Mol Biol. 148:232–238.
2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kashii M, Kamatani T, Nagayama Y, Miyama
A, Tsuboi H and Ebina K: Baseline serum PINP level is associated
with the increase in hip bone mineral density seen with romosozumab
treatment in previously untreated women with osteoporosis.
Osteoporos Int. 34:563–572. 2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Takada J, Dinavahi R, Miyauchi A, Hamaya
E, Hirama T, Libanati C, Nakamura Y, Milmont CE and Grauer A:
Relationship between P1NP, a biochemical marker of bone turnover,
and bone mineral density in patients transitioned from alendronate
to romosozumab or teriparatide: A post hoc analysis of the
STRUCTURE trial. J Bone Miner Metab. 38:310–315. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hattori K and Kanayama Y: Association
between P1NP value and increases in bone mineral density in
patients with postmenopausal osteoporosis treated with romosozumab.
Mod Rheumatol. 34:1047–1055. 2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ishimura E, Nishizawa Y, Inaba M,
Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T
and Morii H: Serum levels of 1,25-dihydroxyvitamin D,
24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed
patients with chronic renal failure. Kidney Int. 55:1019–1027.
1999.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Pignolo RJ: Aging and bone metabolism.
Compr Physiol. 13:4355–4386. 2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
McCalden RW, McGeough JA and Court-Brown
CM: Age-related changes in the compressive strength of cancellous
bone. The relative importance of changes in density and trabecular
architecture. J Bone Joint Surg Am. 79:421–427. 1997.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Chen H, Zhou X, Fujita H, Onozuka M and
Kubo KY: Age-related changes in trabecular and cortical bone
microstructure. Int J Endocrinol. 2013(213234)2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ravaioli F, Pivetti A, Di Macro L,
Chrysanthi C, Frassanito G, Pambianco M, Sicuro C, Gualandi N,
Guasconi T, Pecchini M and Colecchia A: Role of vitamin D in liver
disease and complications of advanced chronic liver disease. Int J
Mol Sci. 23(9016)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Konstantakis C, Tselekouni P, Kalafateli M
and Triantos C: Vitamin D deficiency in patients with liver
cirrhosis. Ann Gastroenterol. 29:297–306. 2016.PubMed/NCBI View Article : Google Scholar
|
